Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04819776 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 417
- Enrollment target
NCT04819776 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 417 participants.
The verdict
NCT04819776, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 417 participants
- Enrollment target
Study Summary
The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.
Interventions
- DRUG Iloperidone
- DRUG Iloperidone Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04819776
The ClinicalTrials.gov registry entry for NCT04819776 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iloperidone is the first listed.
NCT04819776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04819776 about?
NCT04819776 is a clinical study titled "Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder". The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.
What is the current status of trial NCT04819776?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2021-03-22. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT04819776?
The interventions under investigation include: Iloperidone (DRUG), Iloperidone Placebo (DRUG).
Who is sponsoring clinical trial NCT04819776?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.